Monoclonal antibodies protect against pandrug-resistant Klebsiella pneumoniae

The ‘silent pandemic’ caused by antimicrobial resistance requires innovative therapeutic approaches. Human monoclonal antibodies (mAbs), which are among the most transformative and safe drugs in oncology 1 and autoimmunity 2 , are rarely used for infectious diseases and not yet used for antimicrobia...

Full description

Saved in:
Bibliographic Details
Published in:Nature (London) Vol. 646; no. 8087; pp. 1204 - 1213
Main Authors: Roscioli, Emanuele, Zucconi Galli Fonseca, Vittoria, Bosch, Soraya Soledad, Paciello, Ida, Maccari, Giuseppe, Cardinali, Giulia, Batani, Giampiero, Stazzoni, Samuele, Tiseo, Giusy, Giordano, Cesira, Yuwei, Shen, Capoccia, Laura, Cardamone, Dario, Ridelfi, Matteo, Troisi, Marco, Manganaro, Noemi, Mugnaini, Chiara, De Santi, Concetta, Ciabattini, Annalisa, Cerofolini, Linda, Fragai, Marco, Licastro, Danilo, Wyres, Kelly, Dortet, Laurent, Barnini, Simona, Nicolau, David P., Menichetti, Francesco, Falcone, Marco, Abdelraouf, Kamilia, Sala, Claudia, Kabanova, Anna, Rappuoli, Rino
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 30.10.2025
Nature Publishing Group
Subjects:
14/1
631/250/2499
631/250/255/1318
631/326/421
Animals
Anti-Bacterial Agents - pharmacology
Antibiotics
Antibodies
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - isolation & purification
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal - therapeutic use
Antigens
Antimicrobial resistance
Bacteremia - microbiology
Bacteremia - prevention & control
Bacteria
Bacterial Capsules - immunology
Bactericidal activity
Carbapenems
Drug resistance
Drug Resistance, Bacterial - drug effects
Drug Resistance, Multiple, Bacterial - drug effects
Drug Resistance, Multiple, Bacterial - immunology
FDA approval
Female
Flow cytometry
Genomes
Humanities and Social Sciences
Humans
Infectious diseases
Klebsiella
Klebsiella Infections - drug therapy
Klebsiella Infections - immunology
Klebsiella Infections - microbiology
Klebsiella Infections - prevention & control
Klebsiella pneumoniae
Klebsiella pneumoniae - classification
Klebsiella pneumoniae - drug effects
Klebsiella pneumoniae - genetics
Klebsiella pneumoniae - growth & development
Klebsiella pneumoniae - immunology
Klebsiella pneumoniae - pathogenicity
Macrophages
Macrophages - immunology
Macrophages - microbiology
Male
Medical innovations
Mice
Monoclonal antibodies
multidisciplinary
Nosocomial infections
O Antigens - immunology
Pathogens
Science
Science (multidisciplinary)
Septicemia
Virulence
ISSN:0028-0836, 1476-4687, 1476-4687
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract The ‘silent pandemic’ caused by antimicrobial resistance requires innovative therapeutic approaches. Human monoclonal antibodies (mAbs), which are among the most transformative and safe drugs in oncology 1 and autoimmunity 2 , are rarely used for infectious diseases and not yet used for antimicrobial resistance 3 . Here we applied an antigen-agnostic strategy to isolate extremely potent human mAbs against Klebsiella pneumoniae sequence type 147 (ST147), a hypervirulent and pandrug-resistant lineage that is spreading globally. Isolated mAbs target the KL64 capsule and the O-antigen. However, although mAbs displayed bactericidal activity in the picomolar range in vitro, only the capsule-specific mAbs were protective against fulminant bloodstream infection by ST147 and two geographically and genetically distant carbapenem-resistant KL64-bearing K. pneumoniae . Protection observed in vivo correlated with in vitro bacterial uptake by macrophages and enchained bacterial growth. Our study thus describes a mAb that protects against pandrug-resistant K. pneumoniae and provides a strategy to isolate mAbs and identify mAbs that confer protection against bacteria with antimicrobial resistance. Capsule-specific human monoclonal antibodies are protective against bloodstream infection by Klebsiella pneumoniae sequence type 147 in a mouse model of septicaemia, and could provide a useful strategy against pathogens with antimicrobial resistance.
AbstractList The ‘silent pandemic’ caused by antimicrobial resistance requires innovative therapeutic approaches. Human monoclonal antibodies (mAbs), which are among the most transformative and safe drugs in oncology 1 and autoimmunity 2 , are rarely used for infectious diseases and not yet used for antimicrobial resistance 3 . Here we applied an antigen-agnostic strategy to isolate extremely potent human mAbs against Klebsiella pneumoniae sequence type 147 (ST147), a hypervirulent and pandrug-resistant lineage that is spreading globally. Isolated mAbs target the KL64 capsule and the O-antigen. However, although mAbs displayed bactericidal activity in the picomolar range in vitro, only the capsule-specific mAbs were protective against fulminant bloodstream infection by ST147 and two geographically and genetically distant carbapenem-resistant KL64-bearing K. pneumoniae . Protection observed in vivo correlated with in vitro bacterial uptake by macrophages and enchained bacterial growth. Our study thus describes a mAb that protects against pandrug-resistant K. pneumoniae and provides a strategy to isolate mAbs and identify mAbs that confer protection against bacteria with antimicrobial resistance. Capsule-specific human monoclonal antibodies are protective against bloodstream infection by Klebsiella pneumoniae sequence type 147 in a mouse model of septicaemia, and could provide a useful strategy against pathogens with antimicrobial resistance.
The 'silent pandemic' caused by antimicrobial resistance requires innovative therapeutic approaches. Human monoclonal antibodies (mAbs), which are among the most transformative and safe drugs in oncology1 and autoimmunity2, are rarely used for infectious diseases and not yet used for antimicrobial resistance3. Here we applied an antigen-agnostic strategy to isolate extremely potent human mAbs against Klebsiella pneumoniae sequence type 147 (ST147), a hypervirulent and pandrug-resistant lineage that is spreading globally. Isolated mAbs target the KL64 capsule and the O-antigen. However, although mAbs displayed bactericidal activity in the picomolar range in vitro, only the capsule-specific mAbs were protective against fulminant bloodstream infection by ST147 and two geographically and genetically distant carbapenem-resistant KL64-bearing K. pneumoniae. Protection observed in vivo correlated with in vitro bacterial uptake by macrophages and enchained bacterial growth. Our study thus describes a mAb that protects against pandrug-resistant K. pneumoniae and provides a strategy to isolate mAbs and identify mAbs that confer protection against bacteria with antimicrobial resistance.The 'silent pandemic' caused by antimicrobial resistance requires innovative therapeutic approaches. Human monoclonal antibodies (mAbs), which are among the most transformative and safe drugs in oncology1 and autoimmunity2, are rarely used for infectious diseases and not yet used for antimicrobial resistance3. Here we applied an antigen-agnostic strategy to isolate extremely potent human mAbs against Klebsiella pneumoniae sequence type 147 (ST147), a hypervirulent and pandrug-resistant lineage that is spreading globally. Isolated mAbs target the KL64 capsule and the O-antigen. However, although mAbs displayed bactericidal activity in the picomolar range in vitro, only the capsule-specific mAbs were protective against fulminant bloodstream infection by ST147 and two geographically and genetically distant carbapenem-resistant KL64-bearing K. pneumoniae. Protection observed in vivo correlated with in vitro bacterial uptake by macrophages and enchained bacterial growth. Our study thus describes a mAb that protects against pandrug-resistant K. pneumoniae and provides a strategy to isolate mAbs and identify mAbs that confer protection against bacteria with antimicrobial resistance.
The 'silent pandemic' caused by antimicrobial resistance requires innovative therapeutic approaches. Human monoclonal antibodies (mAbs), which are among the most transformative and safe drugs in oncology and autoimmunity , are rarely used for infectious diseases and not yet used for antimicrobial resistance . Here we applied an antigen-agnostic strategy to isolate extremely potent human mAbs against Klebsiella pneumoniae sequence type 147 (ST147), a hypervirulent and pandrug-resistant lineage that is spreading globally. Isolated mAbs target the KL64 capsule and the O-antigen. However, although mAbs displayed bactericidal activity in the picomolar range in vitro, only the capsule-specific mAbs were protective against fulminant bloodstream infection by ST147 and two geographically and genetically distant carbapenem-resistant KL64-bearing K. pneumoniae. Protection observed in vivo correlated with in vitro bacterial uptake by macrophages and enchained bacterial growth. Our study thus describes a mAb that protects against pandrug-resistant K. pneumoniae and provides a strategy to isolate mAbs and identify mAbs that confer protection against bacteria with antimicrobial resistance.
The ‘silent pandemic’ caused by antimicrobial resistance requires innovative therapeutic approaches. Human monoclonal antibodies (mAbs), which are among the most transformative and safe drugs in oncology1 and autoimmunity2, are rarely used for infectious diseases and not yet used for antimicrobial resistance3. Here we applied an antigen-agnostic strategy to isolate extremely potent human mAbs against Klebsiella pneumoniae sequence type 147 (ST147), a hypervirulent and pandrug-resistant lineage that is spreading globally. Isolated mAbs target the KL64 capsule and the O-antigen. However, although mAbs displayed bactericidal activity in the picomolar range in vitro, only the capsule-specific mAbs were protective against fulminant bloodstream infection by ST147 and two geographically and genetically distant carbapenem-resistant KL64-bearing K. pneumoniae. Protection observed in vivo correlated with in vitro bacterial uptake by macrophages and enchained bacterial growth. Our study thus describes a mAb that protects against pandrug-resistant K. pneumoniae and provides a strategy to isolate mAbs and identify mAbs that confer protection against bacteria with antimicrobial resistance.Capsule-specific human monoclonal antibodies are protective against bloodstream infection by Klebsiella pneumoniae sequence type 147 in a mouse model of septicaemia, and could provide a useful strategy against pathogens with antimicrobial resistance.
Author Bosch, Soraya Soledad
Tiseo, Giusy
Zucconi Galli Fonseca, Vittoria
Paciello, Ida
Abdelraouf, Kamilia
De Santi, Concetta
Giordano, Cesira
Stazzoni, Samuele
Dortet, Laurent
Kabanova, Anna
Nicolau, David P.
Yuwei, Shen
Batani, Giampiero
Barnini, Simona
Menichetti, Francesco
Ciabattini, Annalisa
Ridelfi, Matteo
Rappuoli, Rino
Cerofolini, Linda
Capoccia, Laura
Cardinali, Giulia
Mugnaini, Chiara
Sala, Claudia
Fragai, Marco
Roscioli, Emanuele
Maccari, Giuseppe
Troisi, Marco
Licastro, Danilo
Wyres, Kelly
Falcone, Marco
Cardamone, Dario
Manganaro, Noemi
Author_xml – sequence: 1
  givenname: Emanuele
  orcidid: 0000-0003-4125-4632
  surname: Roscioli
  fullname: Roscioli, Emanuele
  organization: Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences
– sequence: 2
  givenname: Vittoria
  orcidid: 0000-0002-4593-2544
  surname: Zucconi Galli Fonseca
  fullname: Zucconi Galli Fonseca, Vittoria
  organization: Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Department of Biotechnology, Chemistry and Pharmacy, University of Siena
– sequence: 3
  givenname: Soraya Soledad
  orcidid: 0000-0003-1459-4463
  surname: Bosch
  fullname: Bosch, Soraya Soledad
  organization: Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences
– sequence: 4
  givenname: Ida
  surname: Paciello
  fullname: Paciello, Ida
  organization: Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences
– sequence: 5
  givenname: Giuseppe
  surname: Maccari
  fullname: Maccari, Giuseppe
  organization: Data Science for Health (DASCH) Lab, Fondazione Toscana Life Sciences
– sequence: 6
  givenname: Giulia
  surname: Cardinali
  fullname: Cardinali, Giulia
  organization: Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Department of Biotechnology, Chemistry and Pharmacy, University of Siena
– sequence: 7
  givenname: Giampiero
  surname: Batani
  fullname: Batani, Giampiero
  organization: Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences
– sequence: 8
  givenname: Samuele
  orcidid: 0000-0002-1579-6895
  surname: Stazzoni
  fullname: Stazzoni, Samuele
  organization: Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences
– sequence: 9
  givenname: Giusy
  surname: Tiseo
  fullname: Tiseo, Giusy
  organization: Department of Clinical and Experimental Medicine, Infectious Diseases Unit, University of Pisa
– sequence: 10
  givenname: Cesira
  surname: Giordano
  fullname: Giordano, Cesira
  organization: Microbiology Unit, Azienda Universitaria Ospedaliera Pisana
– sequence: 11
  givenname: Shen
  surname: Yuwei
  fullname: Yuwei, Shen
  organization: Center for Anti-infective Research and Development, Hartford Hospital
– sequence: 12
  givenname: Laura
  orcidid: 0009-0001-4172-1117
  surname: Capoccia
  fullname: Capoccia, Laura
  organization: Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Department of Medical Biotechnologies, University of Siena
– sequence: 13
  givenname: Dario
  surname: Cardamone
  fullname: Cardamone, Dario
  organization: Data Science for Health (DASCH) Lab, Fondazione Toscana Life Sciences
– sequence: 14
  givenname: Matteo
  surname: Ridelfi
  fullname: Ridelfi, Matteo
  organization: Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Department of Biotechnology, Chemistry and Pharmacy, University of Siena
– sequence: 15
  givenname: Marco
  surname: Troisi
  fullname: Troisi, Marco
  organization: Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences
– sequence: 16
  givenname: Noemi
  orcidid: 0000-0001-8512-4704
  surname: Manganaro
  fullname: Manganaro, Noemi
  organization: Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences
– sequence: 17
  givenname: Chiara
  surname: Mugnaini
  fullname: Mugnaini, Chiara
  organization: Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences
– sequence: 18
  givenname: Concetta
  surname: De Santi
  fullname: De Santi, Concetta
  organization: Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences
– sequence: 19
  givenname: Annalisa
  orcidid: 0000-0002-4585-7783
  surname: Ciabattini
  fullname: Ciabattini, Annalisa
  organization: Department of Medical Biotechnologies, University of Siena
– sequence: 20
  givenname: Linda
  surname: Cerofolini
  fullname: Cerofolini, Linda
  organization: Magnetic Resonance Center (CERM), University of Florence, and Consorzio Interuniversitario Risonanze Magnetiche di Metalloproteine (CIRMMP)
– sequence: 21
  givenname: Marco
  surname: Fragai
  fullname: Fragai, Marco
  organization: Magnetic Resonance Center (CERM), University of Florence, and Consorzio Interuniversitario Risonanze Magnetiche di Metalloproteine (CIRMMP)
– sequence: 22
  givenname: Danilo
  surname: Licastro
  fullname: Licastro, Danilo
  organization: AREA Science Park, Padriciano
– sequence: 23
  givenname: Kelly
  orcidid: 0000-0002-4033-6639
  surname: Wyres
  fullname: Wyres, Kelly
  organization: Department of Infectious Diseases, School of Translational Medicine, Monash University, Centre to Impact AMR, Monash University
– sequence: 24
  givenname: Laurent
  orcidid: 0000-0001-6596-7384
  surname: Dortet
  fullname: Dortet, Laurent
  organization: INSERM, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT/UMRS1184), Université Paris-Saclay, Bacteriology-Hygiene Unit, Bicêtre Hospital Assistance Publique-Hôpitaux de Paris, Carbapenemase-Producing Enterobacteriaceae, Associated French National Reference Center for Antibiotic Resistance
– sequence: 25
  givenname: Simona
  surname: Barnini
  fullname: Barnini, Simona
  organization: Microbiology Unit, Azienda Universitaria Ospedaliera Pisana
– sequence: 26
  givenname: David P.
  surname: Nicolau
  fullname: Nicolau, David P.
  organization: Center for Anti-infective Research and Development, Hartford Hospital
– sequence: 27
  givenname: Francesco
  surname: Menichetti
  fullname: Menichetti, Francesco
  organization: Department of Clinical and Experimental Medicine, Infectious Diseases Unit, University of Pisa
– sequence: 28
  givenname: Marco
  surname: Falcone
  fullname: Falcone, Marco
  organization: Department of Clinical and Experimental Medicine, Infectious Diseases Unit, University of Pisa
– sequence: 29
  givenname: Kamilia
  orcidid: 0000-0003-2524-352X
  surname: Abdelraouf
  fullname: Abdelraouf, Kamilia
  organization: Center for Anti-infective Research and Development, Hartford Hospital
– sequence: 30
  givenname: Claudia
  surname: Sala
  fullname: Sala, Claudia
  organization: Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences
– sequence: 31
  givenname: Anna
  orcidid: 0000-0002-2077-472X
  surname: Kabanova
  fullname: Kabanova, Anna
  email: a.kabanova@toscanalifesciences.org
  organization: Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Tumor Immunology Unit, Fondazione Toscana Life Sciences
– sequence: 32
  givenname: Rino
  orcidid: 0000-0002-8827-254X
  surname: Rappuoli
  fullname: Rappuoli, Rino
  email: rino.rappuoli@biotecnopolo.it
  organization: Fondazione Biotecnopolo di Siena
BackLink https://www.ncbi.nlm.nih.gov/pubmed/41034577$$D View this record in MEDLINE/PubMed
BookMark eNp9kb1v2zAQxYnCRe2k_Qc6BAKydGFL8vilMTCSJqiDLu1MUNLJkCGTDikN-e9L1_kAMmS65ffe3b13RhYhBiTkK2ffOQP7I0uurKZMKMpqqDmFD2TFpdFUamsWZMWYsJRZ0EtylvOOMaa4kZ_IUha9VMasyP19DLEdY_Bj5cM0NLEbMFeHFCdsp8pv_RDyVB186NK8pQnzkKcCVr9GbPKA4-irQ8B5H8Pg8TP52Psx45eneU7-3lz_Wd_Sze-fd-urDW1B2InqVtvGywaNAK9UJ2uQtQGvLXaitryzBhgwCX1f9y3rO6ulsqKu0RstvYBz8u3kW-58mDFPbj_k9nhMwDhnB0JpKJGALujlG3QX51TePVJaG26UPhpePFFzs8fOHdKw9-nRPQdVAHEC2hRzTti_IJy5Yxvu1IYrbbj_bTgoIjiJcoHDFtPr7ndU_wCVvouE
Cites_doi 10.1016/S0008-6215(00)84780-1
10.1016/S1473-3099(23)00572-8
10.3390/biology13040256
10.1016/j.cell.2016.03.017
10.1128/IAI.00693-20
10.1016/j.ijmm.2017.09.012
10.1128/IAI.00678-15
10.1016/j.ijantimicag.2004.10.001
10.1074/jbc.M110.122598
10.1074/jbc.RA117.000646
10.1073/pnas.1717162115
10.1038/s41579-020-00506-3
10.1097/01.CCM.0000217961.75225.E9
10.1371/journal.pcbi.1006986
10.1093/infdis/jiw021
10.3389/fcimb.2023.1108818
10.1038/s41590-018-0106-2
10.2807/1560-7917.ES.2020.25.48.2001779
10.3389/fmicb.2021.691406
10.1080/19420862.2021.2006123
10.3389/fmicb.2022.1080059
10.1074/jbc.M202683200
10.1371/journal.pone.0056847
10.1186/s13073-019-0706-y
10.3390/antibiotics10060691
10.1099/mic.0.28285-0
10.1016/0008-6215(87)80283-5
10.1128/jb.108.3.1304-1309.1971
10.1128/IAI.70.5.2583-2590.2002
10.1093/cid/ciaa586
10.1172/jci.insight.92774
10.1128/IAI.68.5.2402-2409.2000
10.1007/s00262-024-03814-2
10.1016/S2666-5247(21)00268-8
10.1016/j.cmi.2023.11.005
10.1371/journal.pbio.1002344
10.1038/s41467-017-02223-7
10.1016/j.intimp.2021.108305
10.3390/biotech10030019
10.1371/journal.ppat.1011367
10.3201/eid2602.190594
10.1016/j.cell.2021.02.035
10.1099/mgen.0.000102
10.1099/jmm.0.001823
10.1128/AAC.01074-18
10.1128/CVI.00456-16
10.3947/ic.2017.49.1.57
10.1093/cid/ciab457
10.1099/mgen.0.000967
ContentType Journal Article
Copyright The Author(s), under exclusive licence to Springer Nature Limited 2025 Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2025. The Author(s), under exclusive licence to Springer Nature Limited.
The Author(s), under exclusive licence to Springer Nature Limited 2025
Copyright_xml – notice: The Author(s), under exclusive licence to Springer Nature Limited 2025 Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2025. The Author(s), under exclusive licence to Springer Nature Limited.
– notice: The Author(s), under exclusive licence to Springer Nature Limited 2025
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QG
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7TG
7TK
7TM
7TO
7U9
8FD
C1K
FR3
H94
K9.
KL.
M7N
NAPCQ
P64
RC3
SOI
7X8
DOI 10.1038/s41586-025-09391-3
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Ecology Abstracts
Entomology Abstracts (Full archive)
Environment Abstracts
Immunology Abstracts
Meteorological & Geoastrophysical Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Meteorological & Geoastrophysical Abstracts - Academic
Algology Mycology and Protozoology Abstracts (Microbiology C)
ProQuest Nursing and Allied Health Premium
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
Environment Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
Technology Research Database
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
Ecology Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
Entomology Abstracts
Nursing & Allied Health Premium
Genetics Abstracts
Meteorological & Geoastrophysical Abstracts
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
Immunology Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Environment Abstracts
Meteorological & Geoastrophysical Abstracts - Academic
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Virology and AIDS Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
Physics
EISSN 1476-4687
EndPage 1213
ExternalDocumentID 41034577
10_1038_s41586_025_09391_3
Genre Journal Article
GroupedDBID ---
--Z
-DZ
-ET
-~X
.55
.CO
.XZ
07C
0R~
123
186
1OL
29M
2KS
39C
5RE
6TJ
70F
7RV
85S
8WZ
97F
A6W
A7Z
AAHBH
AAHTB
AAIKC
AAKAB
AAMNW
AARCD
AASDW
AAYEP
ABDQB
ABFSG
ABFSI
ABIVO
ABJNI
ABLJU
ABOCM
ABPEJ
ABPPZ
ABUFD
ABWJO
ABZEH
ACBEA
ACBWK
ACGFO
ACGFS
ACGOD
ACIWK
ACKOT
ACMJI
ACNCT
ACPRK
ACSTC
ACWUS
ADBBV
ADFRT
ADUKH
AENEX
AEZWR
AFANA
AFBBN
AFFNX
AFHIU
AFKWF
AFLOW
AFRAH
AFSHS
AGAYW
AGHSJ
AGSOS
AGSTI
AHMBA
AHSBF
AHWEU
AIDUJ
AIXLP
ALFFA
ALMA_UNASSIGNED_HOLDINGS
ALPWD
AMTXH
ARMCB
ASPBG
ATCPS
ATHPR
ATWCN
AVWKF
AXYYD
AZFZN
BENPR
BHPHI
BIN
BKKNO
CJ0
CS3
DU5
E.-
E.L
EAP
EBS
EE.
EPS
EXGXG
F5P
FAC
FEDTE
FQGFK
FSGXE
HG6
HVGLF
HZ~
IAO
ICQ
IEA
IEP
IGS
IH2
IHR
INH
IOF
IPY
KOO
L7B
LGEZI
LOTEE
LSO
M0K
M7P
N9A
NADUK
NAPCQ
NEPJS
NFIDA
NXXTH
O9-
OBC
ODYON
OES
OHH
OMK
OVD
P2P
PV9
RND
RNS
RNT
RNTTT
RXW
SC5
SHXYY
SIXXV
SJN
SNYQT
SOJ
TAE
TAOOD
TBHMF
TDRGL
TN5
TSG
TUS
TWZ
U5U
UKR
UMD
UQL
VVN
WH7
X7M
XIH
XKW
XZL
Y6R
YAE
YFH
YJ6
YNT
YOC
YQT
YR2
YR5
YXB
YZZ
ZCA
~02
~88
~KM
0WA
AAYXX
ARAPS
CITATION
HCIFZ
M2O
TEORI
.-4
.GJ
.HR
00M
08P
1CY
1VR
1VW
2XV
354
3EH
3O-
4.4
41X
41~
42X
4R4
53G
663
79B
7X2
7X7
7XC
88E
88I
8AF
8AO
8C1
8CJ
8FE
8FG
8FH
8FI
8FJ
8G5
8R4
8R5
97L
9M8
A8Z
AAJYS
AAKAS
AAVBQ
ABDBF
ABDPE
ABEFU
ABJCF
ABNNU
ABUWG
ACBNA
ACBTR
ACRPL
ACTDY
ACUHS
ADNMO
ADRHT
ADXHL
ADYSU
ADZCM
AETEA
AEUYN
AFFDN
AFFHD
AFHKK
AFKRA
AGCDD
AGGDT
AGNAY
AGQPQ
AIDAL
AIYXT
AJUXI
APEBS
ARTTT
AZQEC
B0M
BBNVY
BCR
BCU
BDKGC
BEC
BES
BGLVJ
BKEYQ
BKOMP
BKSAR
BLC
BPHCQ
BVXVI
CCPQU
CGR
CUY
CVF
D1I
D1J
D1K
DB5
DO4
DWQXO
EAD
EAS
EAZ
EBC
EBD
EBO
ECC
ECM
EIF
EJD
EMB
EMF
EMH
EMK
EMOBN
EPL
ESE
ESN
ESTFP
ESX
EX3
FA8
FYUFA
GNUQQ
GUQSH
HMCUK
I-F
INR
ISR
ITC
J5H
K6-
KB.
L-9
L6V
LK5
LK8
M1P
M2M
M2P
M7R
M7S
MVM
N4W
NEJ
NPM
OHT
P-O
P62
PATMY
PCBAR
PDBOC
PEA
PHGZM
PHGZT
PJZUB
PM3
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PSYQQ
PTHSS
PYCSY
Q2X
QS-
R05
R4F
RHI
S0X
SJFOW
SKT
SV3
TH9
TUD
UBY
UHB
UKHRP
USG
VOH
WOW
X7L
XOL
YQI
YQJ
YV5
YXA
YYP
YYQ
ZCG
ZE2
ZGI
ZHY
ZKB
ZY4
~7V
~8M
~G0
7QG
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7TG
7TK
7TM
7TO
7U9
8FD
C1K
FR3
H94
K9.
KL.
M7N
P64
RC3
SOI
7X8
AAYZH
ID FETCH-LOGICAL-c328t-6c68ba4be723a55d4934973a68ed2981d87303043ff9fc0fd86458299ea764a23
ISICitedReferencesCount 0
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001585044000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0028-0836
1476-4687
IngestDate Mon Oct 06 16:42:41 EDT 2025
Sat Nov 01 10:55:39 EDT 2025
Sat Nov 15 01:41:52 EST 2025
Sat Nov 29 07:02:40 EST 2025
Thu Oct 30 01:13:17 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 8087
Language English
License 2025. The Author(s), under exclusive licence to Springer Nature Limited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c328t-6c68ba4be723a55d4934973a68ed2981d87303043ff9fc0fd86458299ea764a23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-8827-254X
0000-0002-4593-2544
0000-0002-4585-7783
0000-0003-4125-4632
0000-0002-4033-6639
0000-0003-1459-4463
0000-0001-6596-7384
0000-0001-8512-4704
0000-0002-1579-6895
0000-0003-2524-352X
0009-0001-4172-1117
0000-0002-2077-472X
PMID 41034577
PQID 3266717562
PQPubID 40569
PageCount 10
ParticipantIDs proquest_miscellaneous_3256393936
proquest_journals_3266717562
pubmed_primary_41034577
crossref_primary_10_1038_s41586_025_09391_3
springer_journals_10_1038_s41586_025_09391_3
PublicationCentury 2000
PublicationDate 2025-10-30
PublicationDateYYYYMMDD 2025-10-30
PublicationDate_xml – month: 10
  year: 2025
  text: 2025-10-30
  day: 30
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationSubtitle International weekly journal of science
PublicationTitle Nature (London)
PublicationTitleAbbrev Nature
PublicationTitleAlternate Nature
PublicationYear 2025
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Q Wang (9391_CR22) 2016; 213
K Zhou (9391_CR35) 2020; 26
P Starkova (9391_CR33) 2021; 10
V Kos (9391_CR26) 2010; 285
ME Pennini (9391_CR16) 2017; 8
G Cortés (9391_CR39) 2002; 70
K Abdelraouf (9391_CR30) 2018; 62
N Ravenscroft (9391_CR54) 1987; 167
SK Berry (9391_CR43) 2022; 14
VD Pilato (9391_CR8) 2022; 3
E Diago-Navarro (9391_CR19) 2018; 9
MG Aruta (9391_CR23) 2021; 10
SZ Mirjalili (9391_CR2) 2021; 101
W Wang (9391_CR25) 2023; 13
V Regueiro (9391_CR40) 2006; 152
TS Cohen (9391_CR17) 2017; 2
Z Lapp (9391_CR32) 2021; 73
EH Merrifield (9391_CR27) 1979; 74
J Wang (9391_CR46) 2017; 307
EJ Klemm (9391_CR5) 2018; 115
C Tascini (9391_CR10) 2024; 30
JF Turton (9391_CR13) 2024; 73
PL Wantuch (9391_CR21) 2023; 19
MJ Martin (9391_CR12) 2023; 9
C March (9391_CR41) 2013; 8
9391_CR3
BR Clarke (9391_CR28) 2018; 293
RN De Jong (9391_CR29) 2016; 14
K Toledo-Stuardo (9391_CR1) 2024; 73
BJ Gormus (9391_CR51) 1971; 108
9391_CR4
M Troisi (9391_CR14) 2022; 13
M Falcone (9391_CR24) 2020; 25
E Andreano (9391_CR50) 2021; 184
F Nonne (9391_CR55) 2024; 13
TK Held (9391_CR42) 2000; 68
S Gonzalez-Ferrer (9391_CR6) 2021; 89
MJ Martin (9391_CR9) 2021; 118
E Diago-Navarro (9391_CR20) 2017; 24
M Falcone (9391_CR7) 2021; 72
A Kumar (9391_CR38) 2006; 34
H Xiong (9391_CR45) 2016; 165
K Banerjee (9391_CR15) 2022; 10
T Rollenske (9391_CR18) 2018; 19
F Bansept (9391_CR48) 2019; 15
J Wassil (9391_CR44) 2024; 24
F Micoli (9391_CR52) 2021; 19
E Vinogradov (9391_CR53) 2002; 277
H Xiong (9391_CR47) 2015; 83
9391_CR49
JY Park (9391_CR31) 2017; 49
KL Wyres (9391_CR34) 2020; 12
D Zhao (9391_CR36) 2021; 12
J Li (9391_CR11) 2005; 25
J Wang (9391_CR37) 2023; 8
References_xml – volume: 74
  start-page: 241
  year: 1979
  ident: 9391_CR27
  publication-title: Carbohydr. Res.
  doi: 10.1016/S0008-6215(00)84780-1
– volume: 24
  start-page: 308
  year: 2024
  ident: 9391_CR44
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/S1473-3099(23)00572-8
– volume: 13
  start-page: 256
  year: 2024
  ident: 9391_CR55
  publication-title: Biology
  doi: 10.3390/biology13040256
– volume: 165
  start-page: 679
  year: 2016
  ident: 9391_CR45
  publication-title: Cell
  doi: 10.1016/j.cell.2016.03.017
– volume: 89
  year: 2021
  ident: 9391_CR6
  publication-title: Infect. Immun.
  doi: 10.1128/IAI.00693-20
– volume: 9
  year: 2018
  ident: 9391_CR19
  publication-title: mBio
– volume: 307
  start-page: 490
  year: 2017
  ident: 9391_CR46
  publication-title: Int. J. Med. Microbiol.
  doi: 10.1016/j.ijmm.2017.09.012
– volume: 83
  start-page: 3418
  year: 2015
  ident: 9391_CR47
  publication-title: Infect. Immun.
  doi: 10.1128/IAI.00678-15
– volume: 25
  start-page: 11
  year: 2005
  ident: 9391_CR11
  publication-title: Int. J. Antimicrob. Agents
  doi: 10.1016/j.ijantimicag.2004.10.001
– volume: 285
  start-page: 19668
  year: 2010
  ident: 9391_CR26
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M110.122598
– volume: 293
  start-page: 4666
  year: 2018
  ident: 9391_CR28
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.RA117.000646
– ident: 9391_CR4
– volume: 115
  start-page: 12872
  year: 2018
  ident: 9391_CR5
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.1717162115
– volume: 19
  start-page: 287
  year: 2021
  ident: 9391_CR52
  publication-title: Nat. Rev. Microbiol.
  doi: 10.1038/s41579-020-00506-3
– volume: 34
  start-page: 1589
  year: 2006
  ident: 9391_CR38
  publication-title: Crit. Care Med.
  doi: 10.1097/01.CCM.0000217961.75225.E9
– volume: 15
  year: 2019
  ident: 9391_CR48
  publication-title: PLoS Comput. Biol.
  doi: 10.1371/journal.pcbi.1006986
– volume: 213
  start-page: 1800
  year: 2016
  ident: 9391_CR22
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jiw021
– volume: 13
  start-page: 1108818
  year: 2023
  ident: 9391_CR25
  publication-title: Front. Cell. Infect. Microbiol.
  doi: 10.3389/fcimb.2023.1108818
– volume: 19
  start-page: 617
  year: 2018
  ident: 9391_CR18
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-018-0106-2
– volume: 25
  start-page: 2001779
  year: 2020
  ident: 9391_CR24
  publication-title: Eurosurveillance
  doi: 10.2807/1560-7917.ES.2020.25.48.2001779
– volume: 12
  start-page: 691406
  year: 2021
  ident: 9391_CR36
  publication-title: Front. Microbiol.
  doi: 10.3389/fmicb.2021.691406
– volume: 14
  year: 2022
  ident: 9391_CR43
  publication-title: mAbs
  doi: 10.1080/19420862.2021.2006123
– volume: 13
  start-page: 1080059
  year: 2022
  ident: 9391_CR14
  publication-title: Front. Microbiol.
  doi: 10.3389/fmicb.2022.1080059
– volume: 277
  start-page: 25070
  year: 2002
  ident: 9391_CR53
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M202683200
– ident: 9391_CR3
– volume: 8
  start-page: e56847
  year: 2013
  ident: 9391_CR41
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0056847
– volume: 12
  year: 2020
  ident: 9391_CR34
  publication-title: Genome Med.
  doi: 10.1186/s13073-019-0706-y
– volume: 10
  start-page: 691
  year: 2021
  ident: 9391_CR33
  publication-title: Antibiotics
  doi: 10.3390/antibiotics10060691
– volume: 10
  year: 2022
  ident: 9391_CR15
  publication-title: Microbiol. Spectr.
– volume: 152
  start-page: 555
  year: 2006
  ident: 9391_CR40
  publication-title: Microbiology
  doi: 10.1099/mic.0.28285-0
– volume: 167
  start-page: 257
  year: 1987
  ident: 9391_CR54
  publication-title: Carbohydr. Res.
  doi: 10.1016/0008-6215(87)80283-5
– volume: 108
  start-page: 1304
  year: 1971
  ident: 9391_CR51
  publication-title: J. Bacteriol.
  doi: 10.1128/jb.108.3.1304-1309.1971
– volume: 70
  start-page: 2583
  year: 2002
  ident: 9391_CR39
  publication-title: Infect. Immun.
  doi: 10.1128/IAI.70.5.2583-2590.2002
– volume: 72
  start-page: 1871
  year: 2021
  ident: 9391_CR7
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/ciaa586
– volume: 2
  year: 2017
  ident: 9391_CR17
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.92774
– volume: 68
  start-page: 2402
  year: 2000
  ident: 9391_CR42
  publication-title: Infect. Immun.
  doi: 10.1128/IAI.68.5.2402-2409.2000
– volume: 8
  year: 2023
  ident: 9391_CR37
  publication-title: mSphere
– volume: 73
  start-page: 242
  year: 2024
  ident: 9391_CR1
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-024-03814-2
– volume: 3
  start-page: e224
  year: 2022
  ident: 9391_CR8
  publication-title: Lancet Microbe
  doi: 10.1016/S2666-5247(21)00268-8
– volume: 30
  start-page: 398
  year: 2024
  ident: 9391_CR10
  publication-title: Clin. Microbiol. Infect.
  doi: 10.1016/j.cmi.2023.11.005
– volume: 14
  year: 2016
  ident: 9391_CR29
  publication-title: PLoS Biol.
  doi: 10.1371/journal.pbio.1002344
– volume: 8
  year: 2017
  ident: 9391_CR16
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-017-02223-7
– volume: 118
  year: 2021
  ident: 9391_CR9
  publication-title: Proc. Natl. Acad. Sci. USA
– volume: 101
  start-page: 108305
  year: 2021
  ident: 9391_CR2
  publication-title: Int. Immunopharmacol.
  doi: 10.1016/j.intimp.2021.108305
– volume: 10
  start-page: 19
  year: 2021
  ident: 9391_CR23
  publication-title: BioTech
  doi: 10.3390/biotech10030019
– volume: 19
  year: 2023
  ident: 9391_CR21
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.1011367
– volume: 26
  start-page: 289
  year: 2020
  ident: 9391_CR35
  publication-title: Emerg. Infect. Dis.
  doi: 10.3201/eid2602.190594
– volume: 184
  start-page: 1821
  year: 2021
  ident: 9391_CR50
  publication-title: Cell
  doi: 10.1016/j.cell.2021.02.035
– ident: 9391_CR49
  doi: 10.1099/mgen.0.000102
– volume: 73
  start-page: 001823
  year: 2024
  ident: 9391_CR13
  publication-title: J. Med. Microbiol.
  doi: 10.1099/jmm.0.001823
– volume: 62
  year: 2018
  ident: 9391_CR30
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.01074-18
– volume: 24
  year: 2017
  ident: 9391_CR20
  publication-title: Clin. Vaccine Immunol.
  doi: 10.1128/CVI.00456-16
– volume: 49
  start-page: 57
  year: 2017
  ident: 9391_CR31
  publication-title: Infect. Chemother.
  doi: 10.3947/ic.2017.49.1.57
– volume: 73
  start-page: 1431
  year: 2021
  ident: 9391_CR32
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/ciab457
– volume: 9
  year: 2023
  ident: 9391_CR12
  publication-title: Microb. Genomics
  doi: 10.1099/mgen.0.000967
SSID ssj0005174
Score 2.4988236
Snippet The ‘silent pandemic’ caused by antimicrobial resistance requires innovative therapeutic approaches. Human monoclonal antibodies (mAbs), which are among the...
The 'silent pandemic' caused by antimicrobial resistance requires innovative therapeutic approaches. Human monoclonal antibodies (mAbs), which are among the...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Publisher
StartPage 1204
SubjectTerms 14/1
631/250/2499
631/250/255/1318
631/326/421
Animals
Anti-Bacterial Agents - pharmacology
Antibiotics
Antibodies
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - isolation & purification
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal - therapeutic use
Antigens
Antimicrobial resistance
Bacteremia - microbiology
Bacteremia - prevention & control
Bacteria
Bacterial Capsules - immunology
Bactericidal activity
Carbapenems
Drug resistance
Drug Resistance, Bacterial - drug effects
Drug Resistance, Multiple, Bacterial - drug effects
Drug Resistance, Multiple, Bacterial - immunology
FDA approval
Female
Flow cytometry
Genomes
Humanities and Social Sciences
Humans
Infectious diseases
Klebsiella
Klebsiella Infections - drug therapy
Klebsiella Infections - immunology
Klebsiella Infections - microbiology
Klebsiella Infections - prevention & control
Klebsiella pneumoniae
Klebsiella pneumoniae - classification
Klebsiella pneumoniae - drug effects
Klebsiella pneumoniae - genetics
Klebsiella pneumoniae - growth & development
Klebsiella pneumoniae - immunology
Klebsiella pneumoniae - pathogenicity
Macrophages
Macrophages - immunology
Macrophages - microbiology
Male
Medical innovations
Mice
Monoclonal antibodies
multidisciplinary
Nosocomial infections
O Antigens - immunology
Pathogens
Science
Science (multidisciplinary)
Septicemia
Virulence
Title Monoclonal antibodies protect against pandrug-resistant Klebsiella pneumoniae
URI https://link.springer.com/article/10.1038/s41586-025-09391-3
https://www.ncbi.nlm.nih.gov/pubmed/41034577
https://www.proquest.com/docview/3266717562
https://www.proquest.com/docview/3256393936
Volume 646
WOSCitedRecordID wos001585044000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAQT
  databaseName: Nature
  customDbUrl:
  eissn: 1476-4687
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0005174
  issn: 0028-0836
  databaseCode: RNT
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://www.nature.com
  providerName: Nature Publishing
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3di9QwEA_eqeCLeOfX6nlUEFFqcLdJ8_Eosqviucq5B4svJU3To1DbdbuV87930qatRxHOB1noluzShJlfk5nMLzMIPUuCRBhYunGotcA0kQmONfg8RofJVMZBLKluik3w5VKs1_KLo41VTTkBXhTi4kJu_quqoQ2UbY_O_oO6-4dCA9yD0uEKaofrlRQPb2mp82aDD6SWxaXlCfouH4OvzlUGFqEPk0Cyrc8xeNvWgix2_sfcxFVmyVD-pjA1jDdTl3hCyyYH6J81QPpNhFObErNsT1rPv6uiNnkPmG-1Bp8789-pPM_8hWVv68ZitdGRsmU5O8Zi1dal-gqw_KXgKzeJSoYgl866SNEHt4_gtiuCJs2pi7y0MyzlDFPmVlkzbhvN6W0G9wosDWH50iGeSiJnmAwrWBe1X36OFmcnJ9Fqvl493_zAtraYjcG7Qit76HrAQ2mJf6fL1UAEanN194NwR6ug29fjTi-bLyOfZBRPb8yU1R102_kX3psWFwfomikO0c2G56urQ3Tg5vLKe-ESjr-8iz4NkPEGyHgOMp6DjDeCjDdAxhsgcw-dLeart--xK7OBNQnEDjPNRKxobHhAVBgmVBIqOVFMmCSQ4M8IWAXIlJI0lamepolgNtgqpVGcURWQ-2i_KAvzEHk6DbniqRGGUrDTmaI0JrMgSPmMCKr5BPmd9KJNm00lalgQREStrCOQddTIOiITdNQJOHIvWBWBu8E42LwsmKCn_c8wJ9pAlypMWdv_hGB4w4dN0INWMX13FDqjIYehvOo0NTz872N5dIXOHqNbA-KP0P5uW5sn6Ib-ucuq7THa42tx3EDvN6wOmWs
linkProvider Nature Publishing
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Monoclonal+antibodies+protect+against+pandrug-resistant+Klebsiella+pneumoniae&rft.jtitle=Nature+%28London%29&rft.au=Roscioli%2C+Emanuele&rft.au=Zucconi+Galli+Fonseca%2C+Vittoria&rft.au=Bosch%2C+Soraya+Soledad&rft.au=Paciello%2C+Ida&rft.date=2025-10-30&rft.issn=1476-4687&rft.eissn=1476-4687&rft_id=info:doi/10.1038%2Fs41586-025-09391-3&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-0836&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-0836&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-0836&client=summon